Sharps Technology, Inc. (STSSW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sharps Technology, Inc. (STSSW) Financial Services Profile

Sharps Technology Inc., a medical device company specializing in safety syringe technology, operates within the financial services sector. Their focus on ultra-low waste syringes like Sharps Provensa positions them to address the growing demand for efficient medication delivery, while navigating a competitive landscape and financial constraints.

What Is the Investment Thesis for STSSW?

Sharps Technology Inc. presents a high-risk, high-reward investment opportunity within the medical device sector. The company's focus on ultra-low waste syringe technology addresses a growing need for efficient medication delivery, potentially driving adoption of Sharps Provensa. However, the company's negative profit margin of -4155.3% and gross margin of -24.0% indicate significant financial challenges. The company's small market capitalization of $0.00B and high beta of 2.20 suggest high volatility. Growth catalysts include potential partnerships with pharmaceutical companies and healthcare providers, as well as expansion into new markets. The company's ability to secure funding and achieve profitability will be critical to its long-term success. Investors should carefully consider the company's financial position and competitive landscape before investing.

Based on FMP financials and quantitative analysis

STSSW Key Highlights

Sharps Provensa is an ultra-low waste space syringe designed for efficient vaccine and injectable medication administration.

• The company was incorporated in 2017, indicating a relatively short operating history.
• Headquartered in Melville, New York, Sharps Technology focuses on the U.S. market.
• The company has a negative profit margin of -4155.3%, reflecting significant financial challenges.
• The company has a negative gross margin of -24.0%, indicating challenges in controlling production costs.

Who Are STSSW's Competitors?

STSSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STSSW's Key Strengths?

Innovative ultra-low waste syringe technology.

• Focus on a growing market segment.
• Potential for strong partnerships.
• Experienced management team.

What Are STSSW's Weaknesses?

Limited operating history.

• Negative profit margin.
• Small market capitalization.
• High beta.

What Could Drive STSSW Stock Higher?

Potential partnerships with pharmaceutical companies to bundle Sharps Provensa with injectable medications.

• Expansion into new geographic markets, particularly developing countries.
• Continued research and development of new syringe technologies.
• Efforts to secure government contracts to supply Sharps Provensa to public health agencies.

What Are the Key Risks for STSSW?

Financial-distress signal — its Altman Z-Score of -7.28 sits in the distress zone (elevated bankruptcy risk).

• Intense competition from established medical device manufacturers.
• Stringent regulatory requirements and potential delays in product approvals.
• Product liability claims and potential recalls.
• Dependence on key suppliers for raw materials and components.
• The company's negative profit margin and limited financial resources.

What Are the Growth Opportunities for STSSW?

• Expansion into new geographic markets represents a significant growth opportunity for Sharps Technology. The company's current focus is primarily on the United States. Expanding into international markets, particularly developing countries with limited access to medication, could drive significant revenue growth. The global market for syringes and needles is projected to reach $25.7 billion by 2027, providing a substantial opportunity for Sharps Technology to expand its market share. Timeline: 2-3 years.
• Partnerships with pharmaceutical companies could accelerate the adoption of Sharps Provensa. Collaborating with pharmaceutical companies to bundle Sharps Provensa with their injectable medications could provide a competitive advantage and drive sales. This strategy could also help Sharps Technology gain access to new markets and distribution channels. The pharmaceutical industry is constantly seeking innovative solutions to improve medication delivery, making partnerships a viable growth strategy. Timeline: 1-2 years.
• Development of new syringe technologies could further differentiate Sharps Technology from its competitors. Investing in research and development to create innovative syringe designs and features could enhance the company's product portfolio and attract new customers. This could include developing syringes with improved safety features, ease of use, or compatibility with specific medications. Continuous innovation is essential for maintaining a competitive edge in the medical device industry. Timeline: Ongoing.
• Securing government contracts to supply Sharps Provensa to public health agencies could provide a stable revenue stream. Government agencies are often seeking cost-effective solutions for vaccine administration and medication delivery. Winning government contracts could provide Sharps Technology with a significant boost in sales and brand recognition. This strategy requires navigating the complex government procurement process and demonstrating the value proposition of Sharps Provensa. Timeline: 1-2 years.
• Acquisition of smaller medical device companies could expand Sharps Technology's product portfolio and market reach. Acquiring companies with complementary technologies or established distribution networks could accelerate the company's growth and diversification. This strategy requires careful due diligence and integration planning to ensure a successful acquisition. The medical device industry is characterized by consolidation, making acquisitions a viable growth strategy. Timeline: 2-3 years.

What Are STSSW's Competitive Advantages?

• Proprietary ultra-low waste syringe technology.
• Focus on a niche market within the medical device industry.
• Potential for strong relationships with pharmaceutical companies.
• Intellectual property protection through patents.

What Does STSSW Do?

Sharps Technology Inc., established in 2017 and based in Melville, New York, is a medical device company dedicated to researching, designing, developing, manufacturing, distributing, and selling safety syringe products. The company's primary offering is Sharps Provensa, an ultra-low waste space syringe engineered to minimize medication waste during the administration of vaccines and injectable medications. This syringe is designed to address the critical need for efficient and cost-effective drug delivery, particularly in scenarios where medication availability is limited or expensive. Since its inception, Sharps Technology has focused on refining its syringe technology and establishing a manufacturing and distribution network within the United States. The company's business model centers around providing healthcare providers and pharmaceutical companies with innovative solutions that improve medication administration practices. Sharps Technology aims to reduce waste, enhance safety, and optimize the utilization of injectable medications. Sharps Technology operates in a competitive market with established players in the medical device and pharmaceutical industries. The company differentiates itself through its focus on ultra-low waste syringe technology and its commitment to innovation. Despite its relatively short operating history, Sharps Technology has made strides in developing and commercializing its Sharps Provensa syringe, positioning itself as a potential disruptor in the medication delivery space.

What Products and Services Does STSSW Offer?

• Researches and designs safety syringe products.
• Develops ultra-low waste space syringe technology.
• Manufactures Sharps Provensa syringes.
• Distributes safety syringe products to healthcare providers.
• Sells safety syringe products in the United States.
• Aims to improve medication administration practices.

How Does STSSW Make Money?

• Sells Sharps Provensa syringes to healthcare providers and pharmaceutical companies.
• Generates revenue through direct sales and distribution agreements.
• Focuses on providing innovative solutions for efficient medication delivery.

What Industry Does STSSW Operate In?

Sharps Technology operates within the medical device industry, specifically focusing on medication delivery systems. The industry is characterized by technological advancements, stringent regulatory requirements, and intense competition. The market for safety syringes is driven by the need to prevent needlestick injuries and reduce the risk of infection transmission. Sharps Technology's focus on ultra-low waste syringe technology aligns with the industry trend towards efficient and cost-effective medication delivery. The company faces competition from established medical device manufacturers and pharmaceutical companies.

Who Are STSSW's Key Customers?

• Hospitals and clinics.
• Pharmaceutical companies.
• Government health agencies.
• Vaccination centers.

Company Profile

Sharps Technology, Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. It is headquartered in Melville, US. The company is led by CEO Paul K. Danner. STSSW has traded publicly since 2026.

How Sharps Technology, Inc. Is Valued

Relative to its peer group, STSSW's quantitative score of 45/100 is roughly in line with the peer average of 54/100.

Return on equity for Sharps Technology, Inc. stands at 11.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.2%, showing how much profit it generates from its asset base. STSSW trades at a trailing price-to-earnings ratio of 0.03, below the Financial Services sector average of ~18x. Its free cash flow yield is -33.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.66 indicates the company holds enough short-term assets to cover its near-term obligations.

Sharps Technology, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.28 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Sharps Technology, Inc. revenue of about $72.4M for fiscal 2026, with EPS near $0.00.

STSSW Financials

STSSW Latest News

No recent news available for STSSW.

STSSW Analyst Consensus

STSSW MoonshotScore

Common Questions About STSSW (Financial Services)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources